Personalized DAPT Benefit Risk Decision Tool
- Personalized DAPT Benefit Risk Decision Tool Clinical Context
This tool supports bedside discussion of dual antiplatelet therapy after acute coronary syndrome by explicitly contrasting ischemic protection with bleeding hazard in the first year after the event. Guideline recommendations describe dual antiplatelet therapy with aspirin plus an oral P2Y12 inhibitor for at least twelve months as the default in patients without high bleeding risk while also emphasizing that prolonged exposure increases major bleeding and can lead to treatment interruption and recurrent events. Clinical scores such as PRECISE DAPT the DAPT score and risk models from the PARIS study help estimate bleeding and ischemic risk to refine decisions, and the Academic Research Consortium criteria define high bleeding risk when at least one major or two minor clinical features are present.
In practice patients with low bleeding risk and high ischemic risk are candidates for potent P2Y12 inhibitor based dual antiplatelet therapy and in selected stable patients extension beyond one year may be considered. Patients with high bleeding risk especially those meeting Academic Research Consortium high bleeding risk criteria can benefit from bleeding reduction strategies including early transition to ticagrelor monotherapy or single antiplatelet therapy after one month and routine proton pump inhibitor use in those at risk of gastrointestinal bleeding. In individuals who also require chronic oral anticoagulant therapy the guideline supports short triple therapy followed by oral anticoagulant plus a P2Y12 inhibitor to reduce bleeding while preserving ischemic protection. Treatment should always be individualized by integrating this structured assessment with coronary anatomy procedural details frailty comorbidities and patient values.
Reference:
Rao SV et al. Two thousand twenty five Acute Coronary Syndromes Management Guideline. Journal of the American College of Cardiology two thousand twenty five. Sections on dual antiplatelet strategies after discharge risk tools for ischemic and bleeding events and Academic Research Consortium high bleeding risk criteria. Key supporting data from Baber U et al J Am Coll Cardiol two thousand sixteen PARIS risk scores Costa F et al Lancet two thousand seventeen PRECISE DAPT score and Yeh RW et al JAMA two thousand sixteen DAPT score for benefit and harm of dual antiplatelet therapy beyond one year.
Discussion
No discussions yet. Be the first to comment.
Create Note
Notes are stored privately on your device only. No login required. Nothing is uploaded or shared.